Literature DB >> 31274379

Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections.

Marcel Muenstermann1, Lea Strobel1, Andreas Klos2, Rick A Wetsel3, Trent M Woodruff4, Jörg Köhl5,6, Kay O Johswich1.   

Abstract

The complement system is pivotal in the defense against invasive disease caused by Neisseria meningitidis (Nme, meningococcus), particularly via the membrane attack complex. Complement activation liberates the anaphylatoxins C3a and C5a, which activate three distinct G-protein coupled receptors, C3aR, C5aR1 and C5aR2 (anaphylatoxin receptors, ATRs). We recently discovered that C5aR1 exacerbates the course of the disease, revealing a downside of complement in Nme sepsis. Here, we compared the roles of all three ATRs during mouse nasal colonization, intraperitoneal infection and human whole blood infection with Nme. Deficiency of complement or ATRs did not alter nasal colonization, but significantly affected invasive disease: Compared to WT mice, the disease was aggravated in C3ar-/- mice, whereas C5ar1-/- and C5ar2-/- mice showed increased resistance to meningococcal sepsis. Surprisingly, deletion of either of the ATRs resulted in lower cytokine/chemokine responses, irrespective of the different susceptibilities of the mice. This was similar in ex vivo human whole blood infection using ATR inhibitors. Neutrophil responses to Nme were reduced in C5ar1-/- mouse blood. Upon stimulation with C5a plus Nme, mouse macrophages displayed reduced phosphorylation of ERK1/2, when C5aR1 or C5aR2 were ablated or inhibited, suggesting that both C5a-receptors prime an initial macrophage response to Nme. Finally, in vivo blockade of C5aR1 alone (PMX205) or along with C5aR2 (A8Δ71-73) resulted in ameliorated disease, whereas neither antagonizing C3aR (SB290157) nor its activation with a "super-agonist" peptide (WWGKKYRASKLGLAR) demonstrated a benefit. Thus, C5aR1 and C5aR2 augment disease pathology and are interesting targets for treatment, whereas C3aR is protective in experimental meningococcal sepsis.

Entities:  

Keywords:  C3a; C3aR; C5a; C5aR1; C5aR2; inflammation; meningococcal disease; sepsis

Mesh:

Substances:

Year:  2019        PMID: 31274379      PMCID: PMC6650196          DOI: 10.1080/21505594.2019.1640035

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  6 in total

Review 1.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

2.  Role of the C5a-C5a receptor axis in the inflammatory responses of the lungs after experimental polytrauma and hemorrhagic shock.

Authors:  Shinjini Chakraborty; Veronika Eva Winkelmann; Sonja Braumüller; Annette Palmer; Anke Schultze; Bettina Klohs; Anita Ignatius; Axel Vater; Michael Fauler; Manfred Frick; Markus Huber-Lang
Journal:  Sci Rep       Date:  2021-01-25       Impact factor: 4.379

3.  Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).

Authors:  Michael Bauer; Andreas Weyland; Gernot Marx; Frank Bloos; Stephan Weber; Norbert Weiler; Stefan Kluge; Anja Diers; Tim Philipp Simon; Ingmar Lautenschläger; Matthias Gründling; Ulrich Jaschinski; Philipp Simon; Axel Nierhaus; Onnen Moerer; Lorenz Reill; Achim Jörres; Renfeng Guo; Markus Loeffler; Konrad Reinhart; Niels Riedemann
Journal:  Crit Care Explor       Date:  2021-11-17

Review 4.  Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation.

Authors:  Zivile Bekassy; Ingrid Lopatko Fagerström; Michael Bader; Diana Karpman
Journal:  Nat Rev Immunol       Date:  2021-11-10       Impact factor: 108.555

Review 5.  C3aR plays both sides in regulating resistance to bacterial infections.

Authors:  Jesse A Corcoran; Brooke A Napier
Journal:  PLoS Pathog       Date:  2022-08-04       Impact factor: 7.464

Review 6.  Circadian Clock and Complement Immune System-Complementary Control of Physiology and Pathology?

Authors:  Pooja Shivshankar; Baharan Fekry; Kristin Eckel-Mahan; Rick A Wetsel
Journal:  Front Cell Infect Microbiol       Date:  2020-08-14       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.